Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Lenvima

(lenvatinib)

lenvatinib 10 MG Oral Capsule [Lenvima]lenvatinib 4 MG Oral Capsule [Lenvima]

NO BLACK BOX WARNING

Dosage & administration

Single Agent Therapy:

* DTC: The recommended dosage is 24 mg orally once daily.

* HCC: The recommended dosage is based on actual body weight: 12 mg orally once daily for patients greater than or equal to 60 kg or 8 mg orally once daily for patients less than 60 kg.

Combination Therapy:

* EC: The recommended dosage is 20 mg orally once daily in combination with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

* RCC: The recommended dosage is:
* 20 mg orally once daily with pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks.

* 18 mg orally once daily with everolimus 5 mg orally once daily.

Modify the recommended daily dose for certain patients with renal or hepatic impairment.

eficacy, safety & testing

Lenvima clinical details

Efficacy & Safety Profile: Advanced Endometrial Carcinoma [Lenvima+Keytruda]

Dosing: Advanced Endometrial Carcinoma [Lenvima+Keytruda]

Efficacy & Safety Profile: Advanced RCC [Lenvima+Keytruda]

Dosing: Advanced RCC [Lenvima+Keytruda]

Adverse Reaction Management: Lenvima+Keytruda

Mechanism of Action (MOA): Advanced RCC

Clinical Trial: Advanced RCC

Efficacy (PFS): Advanced RCC

Efficacy (ORR): Advanced RCC

Efficacy (OS): Advanced RCC

Safety Profile: Advanced RCC

Laboratory Abnormalities: Advanced RCC

Dosing & Administration: Advanced RCC

Dose Modifications: Advanced RCC

Clinical Trial: Unresectable HCC

Efficacy (OS): Unresectable HCC

Efficacy (PFS): Unresectable HCC

Efficacy (ORR): Unresectable HCC

Safety Profile: Unresectable HCC

Laboratory Abnormalities: Unresectable HCC

Dosing: Unresectable HCC

Dose Modifications: Unresectable HCC

Mechanism of Action (MOA): RAI-Refractory DTC

Clinical Trial: RAI-Refractory DTC

Efficacy (PFS): RAI-Refractory DTC

Efficacy (ORR & OS): RAI-Refractory DTC

Safety Profile: RAI-Refractory DTC

Laboratory Abnormalities: RAI-Refractory DTC

Dosing: RAI-Refractory DTC

Dose Modifications: RAI-Refractory DTC

drug label

Lenvima prescribing information

Have more Lenvima questions?

Submit MSL Request

Learn More

Need to report a Lenvima issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Lenvima Prior authorization resources

NOT PROVIDED BY BRANDComplete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

NOT PROVIDED BY BRANDCoverage Authorization Appeals

Learn More

Benefits investigation

Lenvima Intake Form

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Lenvima Financial assistance options

Co-pay savings program

commercial only

Lenvima Intake Form

Enroll in Patient Savings Program - Only HCP Office & Speciality Pharmacies Can Enroll Patients

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Lenvima Temporary Supply Program Form

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Eisai Patient Assistance Program Enrollment Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Lenvima Patient education

Getting started on Lenvima

NOT PROVIDED BY BRANDInstructions For Use: Unresectable HCC

NOT PROVIDED BY BRANDInstructions For Use: Advanced RCC

NOT PROVIDED BY BRANDInstructions For Use: RAI-Refractory DTC

NOT PROVIDED BY BRANDInstructions For Use: Advanced Endometrial Carcinoma [Lenvima+Keytruda]

NOT PROVIDED BY BRANDInstructions For Use: Advanced RCC [Lenvima+Keytruda]